Download PDF
Thromb Haemost 2024; 124(01): 004-019
DOI: 10.1055/s-0043-1771304
Coagulation and Fibrinolysis

Brain Expression of CPB2 and Effects of Cpb2 Deficiency in Mouse Models of Behavior

Joost C. M. Meijers
1   Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands
2   Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, The Netherlands
3   Department of Molecular Hematology, Sanquin Research, Amsterdam, The Netherlands
,
Johanneke van der Harst   *
4   DeltaPhenomics B.V., Schaijk, The Netherlands
,
Pauline F. Marx   **
1   Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands
,
Peyman Sahbaie
5   Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California, United States
6   Anesthesiology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States
,
David J. Clark 
5   Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California, United States
6   Anesthesiology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States
,
John Morser 
7   Division of Hematology, Stanford University School of Medicine, Stanford, California, United States
8   Palo Alto Institute of Research and Education, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, United States
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints


Abstract

Background Procarboxypeptidase B2 (proCPB2 or TAFI) is a zymogen that after activation cleaves C-terminal basic residues from peptides or proteins with many identified targets. A splice variant of CPB2 has been found in the brain lacking essential residues for its carboxypeptidase function. The aim was to determine CPB2 expression in the brain and effects of CPB2 deficiency (Cpb2 −/−) on behavior.

Materials and Methods Behavioral effects were tested by comparing Cpb2 −/− mice in short-term (open field and elevated zero maze tests) and long-term (Phenotyper) observations with wild-type (WT) controls.

Results Long-term observation compared day 1 (acclimatizing to novel environment) to day 4 (fully acclimatized) with the inactive (day) and active (night) periods analyzed separately. Brain expression of CPB2 mRNA and protein was interrogated in publicly available databases. Long-term observation demonstrated differences between WT and Cpb2 −/− mice in several parameters. For example, Cpb2 −/− mice moved more frequently on both days 1 and 4, especially in the normally inactive periods. Cpb2 −/− mice spent more time on the shelter and less time in it. Differences were more pronounced on day 4 after the mice had fully acclimatized. In short-term observations, no differences were observed between Cpb2 −/− mice and WT mice. Brain expression of CBP2 was not detectable in the human protein atlas. Databases of single-cell RNAseq did not show expression of CPB2 mRNA in either human or mouse brain.

Conclusion Continuous observation of home-cage behavior suggests that Cpb2 −/− mice are more active than WT mice, show different day–night activity levels, and might have a different way of processing information.

Keywords

alternative splicing - anxiety - behavior - brain - carboxypeptidase B2

Authors' Contribution

J.C.M.M. and J.M. designed the study, interpreted the results, and wrote the manuscript. P.F.M. co-designed and executed the Phenotyper study, and critically reviewed the manuscript. J.v.d.H. supported the design and execution of the Phenotyper study, as well as the data interpretation, and partially wrote the manuscript. P.S. and J.D.C. executed the open field tests, interpreted the results, and critically reviewed the manuscript. All authors approved the final version of the manuscript.


* Current address: Danone Nutricia Research, Utrecht, The Netherlands.


** Current address: Marx Translations, Driebergen, The Netherlands.


Supplementary Material



Publication History

Received: 02 March 2023

Accepted: 20 June 2023

Article published online:
02 August 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271 (28) 16603-16608
    CrossrefPubMedGoogle Scholar
  • 2 Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274 (49) 35046-35052
    CrossrefPubMedGoogle Scholar
  • 3 Willemse JL, Polla M, Olsson T, Hendriks DF. Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development. Clin Chim Acta 2008; 387 (1–2): 158-160
    CrossrefPubMedGoogle Scholar
  • 4 Leung LLK, Morser J. Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity. J Thromb Haemost 2018; 16: 1474-1486
    CrossrefPubMedGoogle Scholar
  • 5 Nagashima M, Yin ZF, Zhao L. et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109 (01) 101-110
    CrossrefPubMedGoogle Scholar
  • 6 Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110 (09) 1275-1282
    CrossrefPubMedGoogle Scholar
  • 7 te Velde EA, Wagenaar GT, Reijerkerk A. et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1 (10) 2087-2096
    CrossrefPubMedGoogle Scholar
  • 8 Asai S, Sato T, Tada T. et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004; 173 (07) 4669-4674
    CrossrefPubMedGoogle Scholar
  • 9 Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?. J Thromb Haemost 2010; 8 (05) 868-876
    CrossrefPubMedGoogle Scholar
  • 10 Wyseure T, Yang T, Zhou JY. et al. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding. JCI Insight 2019; 4 (19) e128379
    CrossrefPubMedGoogle Scholar
  • 11 Shao Z, Nishimura T, Leung LL, Morser J. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J Thromb Haemost 2015; 13 (06) 1090-1102
    CrossrefPubMedGoogle Scholar
  • 12 Renckens R, Roelofs JJ, ter Horst SA. et al. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol 2005; 175 (10) 6764-6771
    CrossrefPubMedGoogle Scholar
  • 13 Bruno NE, Yano Y, Takei Y. et al. Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. J Thromb Haemost 2008; 6 (01) 139-146
    CrossrefPubMedGoogle Scholar
  • 14 Bruno NE, Yano Y, Takei Y. et al. Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb Haemost 2008; 100 (01) 90-100
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277 (02) 1021-1030
    CrossrefPubMedGoogle Scholar
  • 16 Brouwers GJ, Vos HL, Leebeek FW. et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98 (06) 1992-1993
    CrossrefPubMedGoogle Scholar
  • 17 Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80 (06) 949-955
    PubMedGoogle Scholar
  • 18 Song JJ, Hwang I, Cho KH. et al; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis (CLEAR) Registry. Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest 2011; 121 (09) 3517-3527
    PubMedGoogle Scholar
  • 19 Isordia-Salas I, Martínez-Marino M, Alberti-Minutti P. et al. Genetic polymorphisms associated with thrombotic disease comparison of two territories: myocardial infarction and ischemic stroke. Dis Markers 2019; 2019: 3745735
    CrossrefPubMedGoogle Scholar
  • 20 Mertens JC, Leenaerts D, Brouns R. et al. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is associated with stroke progression, outcome and blood-brain barrier dysfunction. J Thromb Haemost 2018; 16 (02) 342-348
    CrossrefPubMedGoogle Scholar
  • 21 Wang YX, da Cunha V, Vincelette J. et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97 (01) 54-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Noguchi K, Edo N, Miyoshi N. et al. Fibrinolytic potential of DS-1040, a novel orally available inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). Thromb Res 2018; 168: 96-101
    CrossrefPubMedGoogle Scholar
  • 23 Zhou J, Kochan J, Yin O. et al. A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. J Thromb Haemost 2017; 15 (05) 961-971
    CrossrefPubMedGoogle Scholar
  • 24 Vanassche T, Rosovsky RP, Moustafa F. et al. DSG. Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study. J Thromb Haemost 2023 (e-pub ahead of print) DOI: 10.1016/j.jtha.2023.04.037.
    CrossrefPubMedGoogle Scholar
  • 25 Wyseure T, Rubio M, Denorme F. et al. Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke. Blood 2015; 125 (08) 1325-1332
    CrossrefPubMedGoogle Scholar
  • 26 Durand A, Chauveau F, Cho TH. et al. Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke. Cerebrovasc Dis 2014; 38 (04) 268-275
    CrossrefPubMedGoogle Scholar
  • 27 Denorme F, Wyseure T, Peeters M. et al. Inhibition of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice. Stroke 2016; 47 (09) 2419-2422
    CrossrefPubMedGoogle Scholar
  • 28 Orbe J, Alexandru N, Roncal C. et al. Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke. Thromb Res 2015; 136 (02) 445-450
    CrossrefPubMedGoogle Scholar
  • 29 Kraft P, Schwarz T, Meijers JC, Stoll G, Kleinschnitz C. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One 2010; 5 (07) e11658
    CrossrefPubMedGoogle Scholar
  • 30 Matsumoto A, Itoh K, Matsumoto R. A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur J Neurosci 2000; 12 (01) 227-238
    CrossrefPubMedGoogle Scholar
  • 31 Lin JH, Novakovic D, Rizzo CM. et al. The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. Thromb Haemost 2013; 109 (06) 1033-1044
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Matsumoto A, Itoh K, Seki T, Motozaki K, Matsuyama S. Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. Eur J Neurosci 2001; 13 (09) 1653-1657
    CrossrefPubMedGoogle Scholar
  • 33 Bouma BN, Marx PF, Mosnier LO, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101 (05) 329-354
    CrossrefPubMedGoogle Scholar
  • 34 Mook-Kanamori BB, Valls Serón M, Geldhoff M. et al. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. J Thromb Haemost 2015; 13 (11) 2076-2086
    CrossrefPubMedGoogle Scholar
  • 35 Maroteaux G, Loos M, van der Sluis S. et al; NeuroBSIK Mouse Phenomics Consortium. High-throughput phenotyping of avoidance learning in mice discriminates different genotypes and identifies a novel gene. Genes Brain Behav 2012; 11 (07) 772-784
    CrossrefPubMedGoogle Scholar
  • 36 Spruijt BM, Peters SM, de Heer RC, Pothuizen HH, van der Harst JE. Reproducibility and relevance of future behavioral sciences should benefit from a cross fertilization of past recommendations and today's technology: “Back to the future”. J Neurosci Methods 2014; 234: 2-12
    CrossrefPubMedGoogle Scholar
  • 37 Zou Y, Corniola R, Leu D. et al. Extracellular superoxide dismutase is important for hippocampal neurogenesis and preservation of cognitive functions after irradiation. Proc Natl Acad Sci U S A 2012; 109 (52) 21522-21527
    CrossrefPubMedGoogle Scholar
  • 38 Uhlén M, Fagerberg L, Hallström BM. et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347 (6220) 1260419
    CrossrefPubMedGoogle Scholar
  • 39 Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T. Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids. Neurosci Res 2001; 39 (03) 313-317
    CrossrefPubMedGoogle Scholar
  • 40 Chaudhury D, Colwell CS. Circadian modulation of learning and memory in fear-conditioned mice. Behav Brain Res 2002; 133 (01) 95-108
    CrossrefPubMedGoogle Scholar
  • 41 Peirson SN, Brown LA, Pothecary CA, Benson LA, Fisk AS. Light and the laboratory mouse. J Neurosci Methods 2018; 300: 26-36
    CrossrefPubMedGoogle Scholar
  • 42 de Visser L, van den Bos R, Kuurman WW, Kas MJ, Spruijt BM. Novel approach to the behavioural characterization of inbred mice: automated home cage observations. Genes Brain Behav 2006; 5 (06) 458-466
    CrossrefPubMedGoogle Scholar
  • 43 Loos M, Koopmans B, Aarts E. et al; Neuro-BSIK Mouse Phenomics Consortium. Sheltering behavior and locomotor activity in 11 genetically diverse common inbred mouse strains using home-cage monitoring. PLoS One 2014; 9 (09) e108563
    CrossrefPubMedGoogle Scholar
  • 44 Rahpeymai Y, Hietala MA, Wilhelmsson U. et al. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J 2006; 25 (06) 1364-1374
    CrossrefPubMedGoogle Scholar
  • 45 Stevens B, Allen NJ, Vazquez LE. et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007; 131 (06) 1164-1178
    CrossrefPubMedGoogle Scholar
  • 46 Alexander JJ, Anderson AJ, Barnum SR, Stevens B, Tenner AJ. The complement cascade: Yin-Yang in neuroinflammation–neuro-protection and -degeneration. J Neurochem 2008; 107 (05) 1169-1187
    CrossrefPubMedGoogle Scholar
  • 47 Walker DG, McGeer PL. Complement gene expression in human brain: comparison between normal and Alzheimer disease cases. Brain Res Mol Brain Res 1992; 14 (1–2): 109-116
    CrossrefPubMedGoogle Scholar
  • 48 Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 1998; 188 (03) 431-438
    CrossrefPubMedGoogle Scholar
  • 49 Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 1994; 152 (10) 5050-5059
    CrossrefPubMedGoogle Scholar
  • 50 Shen Y, Lue L, Yang L. et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 2001; 305 (03) 165-168
    CrossrefPubMedGoogle Scholar
  • 51 D'Ambrosio AL, Pinsky DJ, Connolly ES. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 2001; 7 (06) 367-382
    CrossrefPubMedGoogle Scholar
  • 52 Vasthare US, Barone FC, Sarau HM. et al. Complement depletion improves neurological function in cerebral ischemia. Brain Res Bull 1998; 45 (04) 413-419
    CrossrefPubMedGoogle Scholar
  • 53 Zhou Q, Leung LL, Morser J. Both carboxypeptidase B2 and carboxypeptidase n are responsible for inactivation of bradykinin. Res Pract Thromb Haemost 2019; 3: 71
    PubMedGoogle Scholar
  • 54 Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev 2001; 122 (16) 1971-1983
    CrossrefPubMedGoogle Scholar
  • 55 Prat A, Biernacki K, Pouly S, Nalbantoglu J, Couture R, Antel JP. Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol 2000; 59 (10) 896-906
    CrossrefPubMedGoogle Scholar